The effect of Urolitin A (Mitopure®) supplementation on muscle strength in healthy middle-aged adults

This is the ISRCTN registry entry for the ATLAS 2 trial, mirroring the ClinicalTrials.gov listing (NCT07231783). Sponsor is Amazentis SA, Switzerland; funder is Amazentis. Submission date 21 oktober 2025, registration 28 oktober 2025. Studiedesign: randomised, dubbelblind, placebokontrollerad, parallel, single-centre, testing Mitopure at 500 mg and 1000 mg against placebo for six months in healthy adults aged 40-65. Studie runs at Atlantia Clinical Trials, Cork, Ireland, principal investigator Nontokozo Yusuff. Enrolment window december 2025 to april 2027, last-participant-last-visit expected oktober 2027. The plain-English summary states participation offers no direct benefit and poses negligible risk, with standard blood draw, DEXA scan, and fitness-testing procedures. No results are available. This entry exists to give the trial a second, independently searchable registration record, useful for verifying the study is genuinely running rather than abandoned after registration, a known failure mode in supplement research.

n/a - trial ongoing, no results reported